Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases
In the lack of an effective vaccine and antiviral treatment, convalescent plasma (CP) has been a promising therapeutic approach in past pandemics. Accumulating evidence in the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic corroborates the safety of CP therapy and prel...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/8/11/1733 |
| _version_ | 1797548780370788352 |
|---|---|
| author | Marijn Thijssen Timothy Devos Hanieh-Sadat Ejtahed Samad Amini-Bavil-Olyaee Ali Akbar Pourfathollah Mahmoud Reza Pourkarim |
| author_facet | Marijn Thijssen Timothy Devos Hanieh-Sadat Ejtahed Samad Amini-Bavil-Olyaee Ali Akbar Pourfathollah Mahmoud Reza Pourkarim |
| author_sort | Marijn Thijssen |
| collection | DOAJ |
| description | In the lack of an effective vaccine and antiviral treatment, convalescent plasma (CP) has been a promising therapeutic approach in past pandemics. Accumulating evidence in the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic corroborates the safety of CP therapy and preliminary data underline the potential efficacy. Recently, the Food and Drug Administration (FDA) permitted CP therapy for coronavirus disease 2019 (COVID-19) patients under the emergency use authorization, albeit additional clinical studies are still needed. The imminent threat of a second or even multiple waves of COVID-19 has compelled health authorities to delineate and calibrate a feasible preparedness algorithm for deploying CP as an immediate therapeutic intervention. The success of preparedness programs depends on the interdisciplinary actions of multiple actors in politics, science, and healthcare. In this review, we evaluate the current status of CP therapy for COVID-19 patients and address the challenges that confront the implementation of CP. Finally, we propose a pandemic preparedness framework for future waves of the COVID-19 pandemic and unknown pathogen outbreaks. |
| first_indexed | 2024-03-10T15:05:36Z |
| format | Article |
| id | doaj.art-ebbc9d3042454d458077bbbce6fd21e3 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-10T15:05:36Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-ebbc9d3042454d458077bbbce6fd21e32023-11-20T19:52:35ZengMDPI AGMicroorganisms2076-26072020-11-01811173310.3390/microorganisms8111733Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious DiseasesMarijn Thijssen0Timothy Devos1Hanieh-Sadat Ejtahed2Samad Amini-Bavil-Olyaee3Ali Akbar Pourfathollah4Mahmoud Reza Pourkarim5Laboratory for Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, BelgiumDepartment of Haematology, University Hospitals Leuven, 3000 Leuven, BelgiumObesity and Eating Habits Research Centre, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran 1411413137, IranBiosafety Development Group, Cellular Sciences Department, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USADepartment of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, P.O. Box 14115-111, Tehran 14117-13116, IranLaboratory for Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, BelgiumIn the lack of an effective vaccine and antiviral treatment, convalescent plasma (CP) has been a promising therapeutic approach in past pandemics. Accumulating evidence in the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic corroborates the safety of CP therapy and preliminary data underline the potential efficacy. Recently, the Food and Drug Administration (FDA) permitted CP therapy for coronavirus disease 2019 (COVID-19) patients under the emergency use authorization, albeit additional clinical studies are still needed. The imminent threat of a second or even multiple waves of COVID-19 has compelled health authorities to delineate and calibrate a feasible preparedness algorithm for deploying CP as an immediate therapeutic intervention. The success of preparedness programs depends on the interdisciplinary actions of multiple actors in politics, science, and healthcare. In this review, we evaluate the current status of CP therapy for COVID-19 patients and address the challenges that confront the implementation of CP. Finally, we propose a pandemic preparedness framework for future waves of the COVID-19 pandemic and unknown pathogen outbreaks.https://www.mdpi.com/2076-2607/8/11/1733antiviralconvalescent plasmaneutralizing antibodiesCOVID-19SARS-CoV-2pandemic |
| spellingShingle | Marijn Thijssen Timothy Devos Hanieh-Sadat Ejtahed Samad Amini-Bavil-Olyaee Ali Akbar Pourfathollah Mahmoud Reza Pourkarim Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases Microorganisms antiviral convalescent plasma neutralizing antibodies COVID-19 SARS-CoV-2 pandemic |
| title | Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases |
| title_full | Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases |
| title_fullStr | Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases |
| title_full_unstemmed | Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases |
| title_short | Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases |
| title_sort | convalescent plasma against covid 19 a broad spectrum therapeutic approach for emerging infectious diseases |
| topic | antiviral convalescent plasma neutralizing antibodies COVID-19 SARS-CoV-2 pandemic |
| url | https://www.mdpi.com/2076-2607/8/11/1733 |
| work_keys_str_mv | AT marijnthijssen convalescentplasmaagainstcovid19abroadspectrumtherapeuticapproachforemerginginfectiousdiseases AT timothydevos convalescentplasmaagainstcovid19abroadspectrumtherapeuticapproachforemerginginfectiousdiseases AT haniehsadatejtahed convalescentplasmaagainstcovid19abroadspectrumtherapeuticapproachforemerginginfectiousdiseases AT samadaminibavilolyaee convalescentplasmaagainstcovid19abroadspectrumtherapeuticapproachforemerginginfectiousdiseases AT aliakbarpourfathollah convalescentplasmaagainstcovid19abroadspectrumtherapeuticapproachforemerginginfectiousdiseases AT mahmoudrezapourkarim convalescentplasmaagainstcovid19abroadspectrumtherapeuticapproachforemerginginfectiousdiseases |